Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Invest. 2007 May;117(5):1147-54.

Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Author information

  • 1Immunotherapy Program, Department of Pediatrics, MCG Cancer Center, Medical College of Georgia, Augusta, GA 30912, USA. dmunn@mail.mcg.edu

Abstract

Tumors arise from normal cells of the body through genetic mutation. Although such genetic mutation often leads to the expression of abnormal antigens, the immune system fails to respond effectively to these antigens; that is, it is tolerant of these antigens. This acquired state of tolerance must be overcome for cancer immunotherapy to succeed. Indoleamine 2,3-dioxygenase (IDO) is one molecular mechanism that contributes to tumor-induced tolerance. IDO helps create a tolerogenic milieu in the tumor and the tumor-draining lymph nodes, both by direct suppression of T cells and enhancement of local Treg-mediated immunosuppression. It can also function as an antagonist to other activators of antitumor immunity. Therefore, strategies to block IDO might enhance the effectiveness of tumor immunotherapy.

PMID:
17476344
PMCID:
PMC1857253
DOI:
10.1172/JCI31178
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Journal of Clinical Investigation Icon for PubMed Central
    Loading ...
    Support Center